10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-DLL4 Reference Antibody (navicixizumab)

Recombinant Antibody
Catalog # APR10040

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NR61
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	74605

Additional Information


Target/Specificity	DLL4
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information


Name	DLL4
Function	Involved in the Notch signaling pathway as Notch ligand (PubMed:11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed:20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed:17728344).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Expressed in vascular endothelium.

Images


Anti-DLL4 Reference Antibody (navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the



protein is greater than 95%.



The purity of Anti-DLL4 Reference Antibody (navicixizumab) is more than 95%, determined by SEC-HPLC.



Immobilized human VEGF165 His at 2 ug/mL can bind Anti-DLL4 Reference Antibody (navicixizumab), EC50=0.01191 ug/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.